PFE analyst estimates
Pfizer (PFE) analyst ratings, the average price target and its range, and every firm's latest call.
PFE analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 8, 2026 | Cantor Fitzgerald | Pfizer (PFE) PT Raised to $28 at Cantor Fitzgerald on Growing Sector Tailwinds | $28.00 |
| Oct 6, 2026 | Scotiabank | Pfizer price target raised to $33 from $30 at Scotiabank | $33.00 |
| Sep 10, 2026 | HSBC | Pfizer price target raised to $30 from $28 at HSBC | $30.00 |
| Aug 7, 2026 | Guggenheim | Pfizer price target lowered to $31 from $35 at Guggenheim | $31.00 |
| Jul 6, 2026 | HSBC | Pfizer downgraded to Hold from Buy at HSBC | $28.00 |
| May 27, 2026 | UBS | UBS Reiterates Neutral Rating on Pfizer (PFE) | $27.00 |
| May 14, 2026 | Wolfe Research | Pfizer price target raised to $26 from $25 at Wolfe Research | $26.00 |
| Mar 17, 2026 | Morgan Stanley | Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive' | $27.00 |
| Mar 9, 2026 | BMO Capital | BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data | $30.00 |
| Feb 24, 2026 | RBC Capital | RBC Capital Starts Pfizer (PFE) at Underperform | $25.00 |
| Feb 19, 2026 | Barclays | Pfizer initiated with an Underweight at Barclays | $25.00 |
| Feb 12, 2026 | Daiwa | Pfizer downgraded to Neutral from Outperform at Daiwa | $27.00 |
| Jan 27, 2026 | Cantor Fitzgerald | Pfizer price target raised to $27 from $24 at Cantor Fitzgerald | $27.00 |
| Jan 6, 2026 | UBS | Pfizer assumed with a Neutral at UBS | $25.00 |
| Dec 17, 2025 | Wolfe Research | Pfizer (PFE) PT Lowered to $24 at Wolfe Research | $24.00 |
- 14 firms rate PFE: 5 buy, 8 hold, 1 sell.
- The average price target is $29.17 from 6 analysts, from $26.00 to $33.00.
Updated 2026-11-02 17:50 UTC